An Overview of the Neurotrophic and Neuroprotective Properties of the Psychoactive Drug Lithium as an Autophagy Modulator in Neurodegenerative Conditions

For both short-term and long-term treatment of bipolar disorder, lithium is a prototypical mood stabilizer. Lithium's neuroprotective properties were revealed by cumulative translational research, which opened the door to reforming the chemical as a treatment for neurodegenerative illnesses. The control of homeostatic systems such as oxidative stress, autophagy, apoptosis, mitochondrial function, and inflammation underlies lithium's neuroprotective characteristics. The fact that lithium inhibits the enzymes inositol monophosphatase (IMPase) and glycogen synthase kinase (GSK)-3 may be the cause of the various intracellular reactions. In this article, we review lithium's neurobiological properties, as demonstrated by its neurotrophic and neuroprotective capabilities, as well as translational studies in cells in culture and in animal models of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Prion disease, amyotrophic lateral sclerosis (ALS), ischemic stroke, and neuronal ceroid lipofuscinosis (NCL), discussing the justification for the drug's use in the treatment of these neurodegenerative disorders.

[1]  N. Wray,et al.  Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial , 2022, Trials.

[2]  Z. Yue,et al.  Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles , 2021, Acta pharmaceutica Sinica. B.

[3]  M. Bähr,et al.  Lithium beyond psychiatric indications: the reincarnation of a new old drug , 2021, Neural regeneration research.

[4]  Y. Lecarpentier,et al.  Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway , 2021, Cells.

[5]  S. Smaili,et al.  Lack of Autophagy Induction by Lithium Decreases Neuroprotective Effects in the Striatum of Aged Rats , 2021, Pharmaceutics.

[6]  J. Rinker,et al.  Randomized feasibility trial to assess tolerance and clinical effects of lithium in progressive multiple sclerosis , 2020, Heliyon.

[7]  Seongju Lee,et al.  Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates , 2020, International journal of molecular sciences.

[8]  T. Proikas-Cezanne,et al.  A mouse model for SPG48 reveals a block of autophagic flux upon disruption of adaptor protein complex five , 2019, Neurobiology of Disease.

[9]  S. Lehmann,et al.  Lithium as a disease-modifying agent for prion diseases , 2018, Translational Psychiatry.

[10]  M. Raja,et al.  Huntington's disease and suicidal behavior: The importance of lithium treatment , 2016, Clinical Neurology and Neurosurgery.

[11]  Yong Tae Kwon,et al.  Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies , 2015, Experimental & Molecular Medicine.

[12]  Xin-Yuan Liu,et al.  Lithium Down-regulates Histone Deacetylase 1 (HDAC1) and Induces Degradation of Mutant Huntingtin* , 2013, The Journal of Biological Chemistry.

[13]  Seon-Hee Oh,et al.  Serine 9 and tyrosine 216 phosphorylation of GSK-3β differentially regulates autophagy in acquired cadmium resistance. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  O. Touloumi,et al.  Autophagy and neurodegenerative disorders , 2013, Neural regeneration research.

[15]  Jean-Pierre Julien,et al.  Axonal transport deficits and neurodegenerative diseases , 2013, Nature Reviews Neuroscience.

[16]  D. Rubinsztein,et al.  Autophagy and misfolded proteins in neurodegeneration , 2012, Experimental Neurology.

[17]  Xianglin Shi,et al.  GSK3β signaling is involved in ultraviolet B-induced activation of autophagy in epidermal cells , 2012, International journal of oncology.

[18]  Qinxi Li,et al.  GSK3-TIP60-ULK1 Signaling Pathway Links Growth Factor Deprivation to Autophagy , 2012, Science.

[19]  Jin-A. Lee.  Neuronal Autophagy: A Housekeeper or a Fighter in Neuronal Cell Survival? , 2012, Experimental neurobiology.

[20]  H. Yang,et al.  Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y , 2011, Neuroscience.

[21]  Masaaki Komatsu,et al.  Autophagy: Renovation of Cells and Tissues , 2011, Cell.

[22]  Changlian Zhu,et al.  Lithium-Mediated Long-Term Neuroprotection in Neonatal Rat Hypoxia–Ischemia is Associated with Antiinflammatory Effects and Enhanced Proliferation and Survival of Neural Stem/Progenitor Cells , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  Jae-Woong Chang,et al.  Lithium rescues the impaired autophagy process in CbCln3Δex7/8/Δex7/8 cerebellar cells and reduces neuronal vulnerability to cell death via IMPase inhibition , 2011, Journal of neurochemistry.

[24]  D. Rubinsztein,et al.  Regulation of mammalian autophagy in physiology and pathophysiology. , 2010, Physiological reviews.

[25]  A. Jalanko,et al.  Neuronal ceroid lipofuscinoses. , 2009, Biochimica et biophysica acta.

[26]  H. Schätzl,et al.  Lithium induces clearance of protease resistant prion protein in prion‐infected cells by induction of autophagy , 2009, Journal of neurochemistry.

[27]  A. Thompson,et al.  Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis , 2009, Neurology.

[28]  C. Bendotti,et al.  Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[29]  S. Pattingre,et al.  JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. , 2008, Molecular cell.

[30]  F. Fornai,et al.  Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium , 2008, Autophagy.

[31]  Gabriele Siciliano,et al.  Lithium delays progression of amyotrophic lateral sclerosis , 2008, Proceedings of the National Academy of Sciences.

[32]  D. Rubinsztein,et al.  A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. , 2008, Human molecular genetics.

[33]  Guido Kroemer,et al.  Self-eating and self-killing: crosstalk between autophagy and apoptosis , 2007, Nature Reviews Molecular Cell Biology.

[34]  S. Maeda,et al.  Assembly of two distinct dimers and higher‐order oligomers from full‐length tau , 2007, The European journal of neuroscience.

[35]  K. Ashe,et al.  Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy , 2007, The Journal of Neuroscience.

[36]  D. Rubinsztein,et al.  Potential therapeutic applications of autophagy , 2007, Nature Reviews Drug Discovery.

[37]  J. Vicencio,et al.  The Inositol Trisphosphate Receptor in the Control of Autophagy , 2007, Autophagy.

[38]  D. Rubinsztein,et al.  Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein* , 2007, Journal of Biological Chemistry.

[39]  D. Rubinsztein,et al.  Inositol and IP3 Levels Regulate Autophagy—Biology and Therapeutic Speculations , 2006, Autophagy.

[40]  D. Rubinsztein,et al.  Lithium induces autophagy by inhibiting inositol monophosphatase , 2005, The Journal of cell biology.

[41]  E. Radue,et al.  Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a , 2005, Neurology.

[42]  Daniel J Klionsky,et al.  Development by self-digestion: molecular mechanisms and biological functions of autophagy. , 2004, Developmental cell.

[43]  C. Phiel,et al.  Molecular targets of lithium action. , 2003, Annual review of pharmacology and toxicology.

[44]  D. Rubinsztein,et al.  Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation* , 2002, The Journal of Biological Chemistry.

[45]  A. Harwood,et al.  A common mechanism of action for three mood-stabilizing drugs , 2002, Nature.

[46]  T. Autti,et al.  MRI of neuronal ceroid lipofuscinosis , 1996, Neuroradiology.

[47]  K S Kosik,et al.  Alzheimer's disease: a cell biological perspective. , 1992, Science.

[48]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[49]  S. Prusiner.  Novel proteinaceous infectious particles cause scrapie. , 1982, Science.

[50]  P. Seglen,et al.  3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[51]  U. Muthane,et al.  Off label use of lithium in the treatment of Huntington's disease: A case series , 2013, Indian journal of psychiatry.

[52]  A. Heiseke,et al.  Autophagy, prion infection and their mutual interactions. , 2010, Current issues in molecular biology.

[53]  S. Mole.  Neuronal ceroid lipofuscinoses. , 1999, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[54]  A. Meijer,et al.  The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. , 1997, European journal of biochemistry.